

Unaudited consolidated financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter ended 30 June 2013 prepared in compliance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB)

All amounts in Indian Rupees lakhs, except share data

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Net Income from Sales and Services</b>	<b>284,492</b>	<b>333,994</b>	<b>254,061</b>	<b>1,162,656</b>
2	<b>Cost of Sales and Services</b>				
	a) (Increase) / decrease in stock-in-trade and work-in-progress	(11,875)	10,783	(12,342)	(13,608)
	b) Consumption of raw materials	94,391	102,999	90,278	383,628
	c) Other expenditure	51,784	51,763	40,716	186,850
3	<b>Gross Profit (1 - 2)</b>	<b>150,192</b>	<b>168,449</b>	<b>135,409</b>	<b>605,786</b>
4	Selling, General and Administrative expenses	87,936	87,224	82,784	335,844
5	Research and Development expenses	24,297	23,261	15,636	76,733
6	Impairment loss on goodwill	-	-	-	1,809
7	Impairment loss on intangibles	-	-	-	5,067
8	Other (income) / expense, net	(3,756)	(16,310)	(2,185)	(24,790)
9	<b>Operating profit (3) - (4 + 5 + 6 + 7 + 8)</b>	<b>41,715</b>	<b>74,274</b>	<b>39,174</b>	<b>211,123</b>
10	Finance (expense) / income, net	(699)	3,973	(2,116)	4,599
11	Share of profit of equity accounted affiliate, net of income taxes	355	257	190	1,044
12	<b>Profit before tax (9 + 10 + 11)</b>	<b>41,371</b>	<b>78,504</b>	<b>37,248</b>	<b>216,766</b>
13	Tax expense	5,278	21,415	3,650	49,004
14	<b>Net Profit after tax (12 - 13)</b>	<b>36,093</b>	<b>57,089</b>	<b>33,598</b>	<b>167,762</b>
15	Extra-ordinary items (net of tax expense)	-	-	-	-
16	<b>Net Profit for the period / year (14 - 15)</b>	<b>36,093</b>	<b>57,089</b>	<b>33,598</b>	<b>167,762</b>
17	<b>Net Profit attributable to:</b>				
	- Equity holders of the Company	36,099	57,101	33,598	167,774
	- Non-controlling interest	(6)	(12)	-	(12)
18	Paid-up equity share capital (Face value of Rs. 5/- each)	8,503	8,492	8,490	8,492
19	Securities premium, retained earnings, share based payment reserve, debenture redemption reserve and other components of equity				719,408
20	<b>Earnings per share before and after extra-ordinary items (in Rupees) per Rs. 5/- share</b>				
	- Basic	21.25	33.62	19.81	98.82
	- Diluted	21.17	33.51	19.74	98.44
		<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	
21	Public shareholding *				
	- Number of shares	97,484,533	97,799,433	97,877,295	97,799,433
	- Percentage of shareholding	57.32	57.59	57.64	57.59
22	Promoters and promoter group shareholding				
	<b>a) Pledged / Encumbered</b>				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
	<b>b) Non-encumbered</b>				
	- Number of shares	43,417,812	43,417,812	43,417,812	43,417,812
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the Company)	25.53	25.56	25.57	25.56
23	Details of items exceeding 10% of total expenditure				
	- Employee cost	55,697	53,488	47,668	204,133

\*Public Shareholding as defined under Clause 40A of the Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt holders)

## Segment reporting (Consolidated)

All amounts in Indian Rupees lakhs

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>Segment wise revenue and results:</b>				
	<b>Segment revenue :</b>				
	a) Pharmaceutical Services and Active Ingredients	68,833	115,846	68,372	362,864
	b) Global Generics	219,025	225,658	190,663	825,629
	c) Proprietary Products	3,191	3,855	3,783	14,679
	d) Others	3,594	2,751	4,343	15,329
	<b>Total</b>	<b>294,643</b>	<b>348,110</b>	<b>267,161</b>	<b>1,218,501</b>
	Less: Inter-segment revenue	10,151	14,116	13,100	55,845
	<b>Net Revenue from operations</b>	<b>284,492</b>	<b>333,994</b>	<b>254,061</b>	<b>1,162,656</b>
<b>2</b>	<b>Segment results :</b>				
	Gross Profit from each segment				
	a) Pharmaceutical Services and Active Ingredients	11,133	34,771	17,205	99,696
	b) Global Generics	134,824	130,238	112,626	487,205
	c) Proprietary Products	2,815	3,415	3,483	13,237
	d) Others	1,420	25	2,095	5,648
	<b>Total</b>	<b>150,192</b>	<b>168,449</b>	<b>135,409</b>	<b>605,786</b>
	Less: Other un-allocable expenditure, net of other income	108,821	89,945	98,161	389,020
	<b>Total profit before tax</b>	<b>41,371</b>	<b>78,504</b>	<b>37,248</b>	<b>216,766</b>

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at Cost.

**Segmental Capital employed**

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above

**Notes:****1 Investor Complaints**

Pending at the beginning of the quarter	Nil
Received during the quarter	4
Disposed off during the quarter	4
Remaining unresolved at the end of the quarter	Nil

**2** The Company has consolidated the financial statements of the following companies:

Dr. Reddy's Farmaceutica Do Brazil Ltda., Dr. Reddy's Laboratories (EU) Limited, Dr. Reddy's Laboratories (UK) Limited, Aurigene Discovery Technologies Limited, Aurigene Discovery Technologies Inc., Cheminor Investments Limited, DRL Impex Limited, Reddy Netherlands B.V., Reddy US Therapeutics Inc., Dr. Reddy's Laboratories (Proprietary) Limited, OOO Dr. Reddy's Laboratories Limited, Promius Pharma LLC, Dr Reddy's Bio-Sciences Limited, Industrias Quimicas Falcon de Mexico SA de CV, Lacock Holdings Limited, Reddy Holding GmbH, betapharm Arzneimittel GmbH, Reddy beta GmbH, beta Institut gemeinnützige GmbH, Dr. Reddy's Laboratories (Australia) Pty Ltd, Dr. Reddy's Laboratories Inc., Reddy Cheminor S.A., Reddy Antilles N.V., Reddy Pharma Iberia, S.A., Reddy Pharma Italia S.p.A, Dr. Reddy's Laboratories SA, Eurobridge Consulting B.V, OOO DRS LLC, Dr. Reddy's New Zealand Limited, Aurigene Discovery Technologies (Malaysia) Sdn Bhd, Dr. Reddy's Laboratories Louisiana LLC, Chiretech Technology Limited, Dr. Reddy's s.r.l., Dr. Reddy's Pharma SEZ Limited, Dr. Reddy's Laboratories International SA, Idea2Enterprises (India) Private Limited, Dr. Reddy's Laboratories Romania-SRL, I-Ven Pharma Capital Limited, Dr. Reddy's Venezuela, C.A., Dr. Reddy's Laboratories Tennessee LLC, Dr Reddy's Laboratories New York Inc, Dr. Reddy's Laboratories, LLC, Ukraine, DRANU, LLC, OctoPlus N.V., OctoPlus Development B.V., OctoPlus Technologies B.V., OctoShare B.V., OctoPlus Sciences B.V., OctoPlus PolyActive Sciences B.V. and Chienna B.V.

**3** Kunshan Rotam Reddy Pharmaceutical Company Limited (a joint venture) has been accounted under the equity method of accounting in accordance with IFRS 11 'Joint Arrangements'.**4** Components of equity as on 31 March 2013 have been restated by Rs. 3,000 Lakhs to reflect the adoption of amendments to IAS 19 'Employee benefits', which is applicable to the Company from 1 April 2013.**5** The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 30 July 2013. The above financial results have been prepared from the consolidated financial statements, which are prepared in accordance with International Financial Reporting Standards and its interpretations (IFRS), as issued by the International Accounting Standards Board (IASB).**6** The Securities and Exchange Board of India (SEBI) issued a circular, dated 5 April 2010 permitting listed entities having subsidiaries to voluntarily submit the Consolidated Financial Statements as per IFRS. Consequent to this, the Company has voluntarily prepared and published unaudited Consolidated Financial Statements as per IFRS for the quarter ended 30 June 2013 and 30 June 2012 and audited Consolidated Financial Statements as per IFRS for the quarter and year ended 31 March 2013.**7** The results for the quarter ended 30 June 2013 have been subject to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.**8 Unaudited financial results of Dr. Reddy's Laboratories Limited (Standalone Information) prepared as per IGAAP**

All amounts in Indian Rupees lakhs

Particulars	Quarter ended			Year ended
	30.06.2013	31.03.2013	30.06.2012	31.03.2013
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Total income from operations	182,162	236,248	180,454	843,401
Profit from ordinary activities before tax	8,336	55,600	21,807	175,313
Profit from ordinary activities after tax	6,486	37,815	17,766	126,547

**Note:**

The unaudited standalone financial results for the quarter ended 30 June 2013 are available on the Stock Exchange's website : [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and also on the Company's website: [www.drreddys.com](http://www.drreddys.com).

By order of the Board  
For Dr. Reddy's Laboratories Limited